Newfeed

HONG KONG, Dec. 15, 2023 /PRNewswire/ — Akeso published two phase Ib clinical results of its innovative CD47 monoclonal antibody ligufalimab (AK117) in combination with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) and treatment-naïve acute myeloid

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: